BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36198529)

  • 21. Novel treatments for relapsed/refractory acute myeloid leukemia with
    Tallis E; Borthakur G
    Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619
    [No Abstract]   [Full Text] [Related]  

  • 22. The most novel of the novel agents for acute myeloid leukemia.
    Perl AE
    Curr Opin Hematol; 2018 Mar; 25(2):81-89. PubMed ID: 29278535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3 Inhibition in Acute Myeloid Leukemia.
    Smith CC
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?
    Pratz KW; Luger SM
    Curr Opin Hematol; 2014 Mar; 21(2):72-8. PubMed ID: 24468836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
    Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
    Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
    Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
    J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting FLT3 to treat leukemia.
    Konig H; Levis M
    Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of crenolanib for FLT3-mutant AML.
    Fathi AT
    Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
    Grunwald MR; Levis MJ
    Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rocky road to personalized medicine in acute myeloid leukaemia.
    Brinda B; Khan I; Parkin B; Konig H
    J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
    Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
    Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
    Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
    Knapper S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 39. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.
    Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X
    Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.